Earnings summaries and quarterly performance for Bluejay Diagnostics.
Executive leadership at Bluejay Diagnostics.
Board of directors at Bluejay Diagnostics.
Research analysts covering Bluejay Diagnostics.
Recent press releases and 8-K filings for BJDX.
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
BJDX
Delisting/Listing Issues
- Bluejay Diagnostics, Inc. announced a 1-for-4 reverse stock split.
- The reverse stock split became effective at 12:01 a.m. Eastern Time on January 29, 2026, with post-split trading commencing the same day on The Nasdaq Capital Market under the existing symbol "BJDX" and a new CUSIP number, 095633608.
- This action reduced the number of issued and outstanding common shares from approximately 2,834,133 to approximately 708,533.
- Stockholders who would otherwise receive fractional shares will instead receive a cash payment.
8 days ago
Bluejay Diagnostics Provides Q3 2025 Corporate and Financial Update
BJDX
Earnings
Guidance Update
New Projects/Investments
- Bluejay Diagnostics reported $3.08 million in cash and cash equivalents and $3.69 million in stockholders' equity as of September 30, 2025.
- The company completed a $3.85 million warrant-inducement financing in April and an additional $4.5 million PIPE financing in October 2025.
- Patient enrollment in the SYMON-II pivotal clinical trial is approximately 50% completed, with a goal to complete sample testing by late 2026 and submit to the FDA in 2027, contingent on further financing.
- Bluejay Diagnostics anticipates needing to raise at least $20 million in additional capital by the end of the 2027 fiscal year to achieve its plans.
- The company strengthened its manufacturing process and commercialization efforts for its Symphony platform through an amended agreement with SanyoSeiko Co., Ltd..
Nov 10, 2025, 9:00 PM
Bluejay Diagnostics Updates on Clinical Milestones and Financing
BJDX
Earnings
New Projects/Investments
Guidance Update
- Bluejay Diagnostics reported $3.08 million in cash and cash equivalents and $3.69 million in stockholders' equity as of September 30, 2025, following $3.85 million and $4.5 million financings completed in April and October 2025, respectively.
- Patient enrollment in the SYMON-II pivotal clinical trial is approximately 50% completed, with a goal to complete sample testing by late 2026 and potential FDA submission in 2027, contingent on further financing.
- The company strengthened its manufacturing and commercialization efforts for the Symphony platform through an amended agreement with SanyoSeiko Co., Ltd..
- Bluejay anticipates needing to raise at least $20 million in additional capital by the end of the 2027 fiscal year to execute its strategic plan.
Nov 10, 2025, 12:30 PM
Bluejay Diagnostics Closes $4.5 Million Private Placement
BJDX
- Bluejay Diagnostics, Inc. (BJDX) announced and closed a $4.5 million private placement on October 10, 2025.
- The offering included the sale of 2,250,000 shares of common stock (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share.
- The Series F warrants have an exercise price of $1.75 per share and are exercisable immediately, expiring 5.5 years from issuance.
- The company received approximately $4.0 million in net proceeds, which will be allocated to funding FDA approval processes, research and development, and general working capital.
- A resale registration statement covering 175,000 shares of common stock and 6,755,000 shares of common stock underlying warrants is expected to be filed by October 24, 2025.
Oct 14, 2025, 10:16 AM
Bluejay Diagnostics Closes Private Placement
BJDX
New Projects/Investments
- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) closed a private placement on October 10, 2025.
- The offering generated gross proceeds of $4.5 million.
- The placement involved the sale of 2,250,000 shares of common stock (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share.
- The net proceeds are intended to fund matters related to FDA approval (including clinical studies), research and development activities, and general working capital needs.
Oct 10, 2025, 9:16 PM
Bluejay Diagnostics Announces Private Placement
BJDX
New Projects/Investments
- Bluejay Diagnostics has entered into definitive agreements for a private placement to sell 2,250,000 shares of common stock (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares of common stock.
- The offering is priced at $2.00 per share for the common stock (or pre-funded warrant) and accompanying warrants, with the Series F warrants having an exercise price of $1.75 per share.
- The private placement is expected to generate $4.5 million in gross proceeds and is anticipated to close on or about October 10, 2025.
- The company intends to use the net proceeds to fund matters related to obtaining FDA approval, other research and development activities, and for general working capital needs.
Oct 9, 2025, 7:15 PM
Bluejay Diagnostics Expands Partnership with SanyoSeiko for Symphony Platform Commercialization
BJDX
New Projects/Investments
Product Launch
- Bluejay Diagnostics (BJDX) and SanyoSeiko Co., Ltd. amended their Master Service and Supply Agreements on October 9, 2025, to expand SanyoSeiko's role in commercializing Bluejay's Symphony platform.
- SanyoSeiko will provide end-to-end support for the Symphony platform, including manufacturing redevelopment, raw material sourcing, contract manufacturing of analyzers and cartridges, fulfillment, and quality control.
- This expanded partnership aims to strengthen Bluejay's supply chain resilience, secure high-quality production capacity, and advance readiness for broader clinical validation and market introduction of the Symphony platform.
- The Symphony platform is a near-patient testing system for sepsis management, but it does not yet have regulatory clearance for marketing as a diagnostic product in the United States.
Oct 9, 2025, 10:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more